Evolva Holding LTD

EVE

Equity

ISIN CH1262055788 / Valor 126205578

SIX Swiss Exchange (2026-06-26)

CHF 2.21+19.7%

Evolva Holding LTD
UMushroom community rating:

2.00 2 votes No rating yet

NegativeNeutralPositive

About company

Evolva Holding Ltd is a Swiss biotechnology company that develops and commercializes ingredients for food, nutrition, health and consumer-product markets by applying synthetic biology and precision fermentation to produce specialty molecules that are difficult, costly or unsustainable to obtain from traditional sources. The company combines discovery and strain‑engineering with process development and scale‑up, then brings products to market through manufacturing partnerships, supply agreements and licensing to ingredient and brand customers. Its commercial focus is on high‑value, low‑volume compounds such as flavor and fragrance molecules and nutritional or bioactive ingredients, together with related contract manufacturing and regulatory pathways needed to support customer adoption.

Summarized from source with an LLMView SourceSector: Healthcare

Profitability

Revenue: CHF 9.44m (2022: CHF 15.54m). Gross result: a gross loss of CHF 2.58m. Operating loss: CHF 92.25m (2022: CHF 40.39m). Net loss for the period: CHF 105.23m (2022: CHF 43.37m). Basic and diluted loss per share: CHF (19.50) (2022: CHF (10.13)).

Major non‑recurring items and impairments

Impairment of intangible assets: CHF 66.28m recorded in 2023. Loss on sale of Evolva AG: CHF 14.63m (recognized in 2023 following the disposal closed 28 December 2023). These items were key drivers of the much larger loss in 2023.

Operating cost drivers

Research & development expenses: CHF 32.12m. Commercial, general & administrative expenses: CHF 57.54m. Total operating expenses: CHF 89.66m — a substantial increase versus 2022 driven by the run‑off, impairments and transaction-related items.

Balance sheet and liquidity

Total assets at liquidation values: CHF 9.83m (prior-year reported on going‑concern: CHF 131.01m). Cash and cash equivalents: CHF 5.84m at 31 Dec 2023 (2022: CHF 5.14m). Total equity: CHF 5.55m (2022: CHF 106.24m) after the deconsolidation and capital adjustments.

Cash flow

Net cash from operating activities: negative CHF 9.25m. Investing cash inflow: +CHF 15.95m (largely proceeds from disposal of subsidiary: CHF 16.41m). Financing cash flow: negative CHF 5.97m. Net change in cash: +CHF 0.72m for the year.

Corporate / structural events

Shareholders approved dissolution and liquidation and delisting on 21 Dec 2023; the Group sold 100% of Evolva AG to Danstar Ferment AG (transaction closed 28 Dec 2023). The 2023 statements were therefore prepared on liquidation values; the report also notes that shareholders later (12 April 2024) approved revocation of the liquidation resolution.

Operations and headcount

Following the disposal, the Group comprised only the holding company at year‑end: 0 employees on 31 Dec 2023 (2022: 50). Trade receivables remained small (CHF 3.99m) in the pared-down group.

Summarized from source with an LLMView Source

Key figures

98.2%1Y

-58.8%3Y

-95.1%5Y

Performance

78.3%1Y

125%3Y

101%5Y

Volatility